Serum amyloid A levels are associated with polymorphic variants in the serum amyloid A 1 and 2 genes
| Autor: | Mark Harbinson, Patrick Nicol, Gareth J. McKay, Kayleigh Griffiths, Rachel V McCarter, Alexander P. Maxwell, Ruth E Hogg |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Inflammation 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine Genetic variation medicine Humans 030212 general & internal medicine Serum amyloid A Gene Aged Serum Amyloid A Protein business.industry Haplotype Heterozygote advantage General Medicine Middle Aged Lipids stomatognathic diseases Endocrinology Cardiovascular Diseases Biomarker (medicine) Female medicine.symptom business Lipoproteins HDL Biomarkers Lipoprotein |
| Zdroj: | Griffiths, K, Maxwell, A P, McCarter, R V, Nicol, P, Hogg, R E, Harbinson, M & McKay, G J 2019, ' Serum amyloid A levels are associated with polymorphic variants in the serum amyloid A 1 and 2 genes ', Irish journal of medical science . https://doi.org/10.1007/s11845-019-01996-8 |
| DOI: | 10.1007/s11845-019-01996-8 |
| Popis: | BACKGROUND: Serum amyloid A (SAA) is secreted by liver hepatocytes in response to increased inflammation whereupon it associates with high-density lipoprotein (HDL) and alters the protein and lipid composition of HDL negating some of its anti-atherogenic properties.AIMS: To identify variants within the SAA gene that may be associated with SAA levels and/or cardiovascular disease (CVD).METHODS: We identified exonic variants within the SAA genes by deoxyribonucleic acid (DNA) Sanger sequencing. We tested the association between SAA variants and serum SAA levels in 246 individuals with and without CVD.RESULTS: Increased SAA was associated with rs2468844 (beta [β] = 1.73; confidence intervals [CI], 1.14-1.75; p = 0.01), rs1136747 (β = 1.53 (CI, 1.11-1.73); p = 0.01) and rs149926073 (β = 3.37 (CI, 1.70-4.00); p = 0.02), while rs1136745 was significantly associated with decreased SAA levels (β = 0.70 (CI, 0.53-0.94); p = 0.02). Homozygous individuals with the SAA1.3 haplotype had significantly lower levels of SAA compared with those with SAA1.1 or SAA1.5 (β = 0.43 (CI, 0.22-0.85); p = 0.02) while SAA1.3/1.5 heterozygotes had significantly higher SAA levels compared with those homozygous for SAA1.1 (β = 2.58 (CI, 1.19-5.57); p = 0.02).CONCLUSIONS: We have identified novel genetic variants in the SAA genes associated with SAA levels, a biomarker of inflammation and chronic disease. The utility of SAA as a biomarker for inflammation and chronic disease may be influenced by underlying genetic variation in baseline levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|